Advertisement

Beverage consumption and paediatric NAFLD

  • Antonella Mosca
  • Claudia Della Corte
  • Maria Rita Sartorelli
  • Francesca Ferretti
  • Francesco Nicita
  • Andrea Vania
  • Valerio Nobili
Review

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in children and adolescents, due to the increased worldwide incidence of obesity among children. It is now clear enough that of diet high in carbohydrates and simple sugars are associated with hepatic steatosis and non-alcoholic steatohepatitis (NASH). Several studies have shown that an increased consumption of simple sugars is also positively associated with overweight and obesity, and related co-morbidities, such as type 2 diabetes, metabolic syndrome and NAFLD. It is difficult to define the role of the various components of soft drinks and energy drinks in the pathogenesis of NAFLD and its progression in NASH, but the major role is played by high calorie and high sugar consumption, mainly fructose. In addition, other components of these beverages (e.g. xanthine) seem to have an important role in the pathogenesis of metabolic disorders, crucial pathways involved in NAFLD/NASH. The drastic reduction in the consumption of energy drinks and soft drinks is an appropriate intervention for the prevention of obesity and NAFLD in young people.

Keywords

NAFLD Adolescents Soft drinks Energy drinks Fructose Alcohol 

Notes

Compliance with ethical standards

Financial support statement

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Conflict of interest

All Authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Ethical approval

In all cited studies, all applicable international, national, and/or institutional guidelines for the care and use of animals were followed and all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the cited studies.

References

  1. 1.
    Malik VS, Popkin BM, Bray GA, Despres J-P, Hu FB (2010) Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk. Circulation 121:1356–1364. doi: 10.1161/CIRCULATIONAHA.109.876185 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Zimmermann MB, Gübeli C, Püntener C, Molinari L (2004) Detection of overweight and obesity in a national sample of 6–12-y-old Swiss children: accuracy and validity of reference values for body mass index from the US Centers for Disease Control and Prevention and the International Obesity Task Force. Am J Clin Nutr 79:838–843PubMedGoogle Scholar
  3. 3.
    Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S (2009) The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 58:1538–1544. doi: 10.1136/gut.2008.171280 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Vos MB, Lavine JE (2013) Dietary fructose in nonalcoholic fatty liver disease. Hepatology 57:2525–2531. doi: 10.1002/hep.26299 CrossRefPubMedGoogle Scholar
  5. 5.
    Atabek ME, Selver Eklioglu B, Akyurek N (2014) Which metabolic syndrome criteria best predict non-alcoholic fatty liver disease in children? Eat Weight Disord 19(4):495–501. doi: 10.1007/s40519-014-0129-0 CrossRefPubMedGoogle Scholar
  6. 6.
    Nielsen SJ, Popkin BM (2004) Changes in beverage intake between 1977 and 2001. Am J Prev Med 27:205–210CrossRefPubMedGoogle Scholar
  7. 7.
    European Food Safety Authority (2010) Scientific opinion on dietary reference values for carbohydrates and dietary fibre. EFSA J 8(3):1462. doi: 10.2903/j.efsa.2010.1462 CrossRefGoogle Scholar
  8. 8.
    Flotta D, Micò R, Nobile CG, Pileggi C, Bianco A, Pavia M (2014) Consumption of energy drinks, alcohol, and alcohol-mixed energy drinks among Italian adolescents. Alcohol Clin Exp Res 38(6):1654–1661. doi: 10.1111/acer.12394 CrossRefPubMedGoogle Scholar
  9. 9.
    Peirson L, Fitzpatrick-Lewis D, Morrison K, Ciliska D, Kenny M, Usman Ali M, Raina P (2015) Prevention of overweight and obesity in children and youth: a systematic review and meta-analysis. CMAJ Open 3(1):E23–E33. doi: 10.9778/cmajo.20140053 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Skinner AC, Skelton JA (2014) Prevalence and trends in obesity and severe obesity among children in the United States, 1999–2012. JAMA Pediatr 168:561–566. doi: 10.1001/jamapediatrics.2014.21 CrossRefPubMedGoogle Scholar
  11. 11.
    Day CP, James OF (1998) Steatohepatitis: a tale of two “hits”? Gastroenterology 114:842–845. doi: 10.1016/S0016-5085(98)70599-2 CrossRefPubMedGoogle Scholar
  12. 12.
    Nobili V, Svegliati-Baroni G, Alisi A (2013) A 360-degree overview of paediatric NAFLD: recent insights. J Hepatol 58:1218–1229. doi: 10.1016/j.jhep.2012.12.003 CrossRefPubMedGoogle Scholar
  13. 13.
    Vitturi N, Soattin M, De Stefano F, Vianello D, Zambon A, Plebani M, Busetto L (2015) Ultrasound, anthropometry and bioimpedance: a comparison in predicting fat deposition in non-alcoholic fatty liver disease. Eat Weight Disord 20(2):241–247. doi: 10.1007/s40519-014-0146-z CrossRefPubMedGoogle Scholar
  14. 14.
    Kawada T (2016) Prediction of non-alcoholic fatty liver disease by obesity indices. Eat Weight Disord 21(2):313–314. doi: 10.1007/s40519-015-0224-x CrossRefPubMedGoogle Scholar
  15. 15.
    Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R (2007) Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol 47:711–717. doi: 10.1016/j.jhep.2007.06.020 CrossRefPubMedGoogle Scholar
  16. 16.
    Bray GA, Popkin BM (2013) Calorie-sweetened beverages and fructose: what have we learned 10 years later. Pediatr Obes 8(4):242–248. doi: 10.1111/j.2047-6310.2013.00171.x CrossRefPubMedGoogle Scholar
  17. 17.
    WHO (2014) Guideline: sugars intake for adults and children: draft guidelines on free sugars released for public consultation. WHO, GenevaGoogle Scholar
  18. 18.
    Scientific Advisory Committee on Nutrition (2014) Draft carbohydrates and health report. The Stationary Office, LondonGoogle Scholar
  19. 19.
    WHO Health Organization (2015) Sugars intake adults and children. Guideline. ISBN: 978 92 4154902 8. http://www.who.int/mediacentre/news/releases/2015/sugar-guideline/en/.
  20. 20.
    Chaloupka FJ, Powell LM, Chriqui JF (2009) Sugar-Sweetened Beverage Taxes and Public Health. http://www.rwjf.org/files/research/20090715beveragetaxresearchbrief.pdf
  21. 21.
    US Beverage Information Group (2013) US beverage alcohol trends. http://www.usdrinksconference.com/assets/files/agenda/US%20Beverage%20Alcohol%20Trends.pdf
  22. 22.
    William N, Fares N, Nimer A (2010) Soft drinks consumption and nonalcoholic fatty liver disease. World J Gastroenterol 16(21):2579–2588. doi: 10.3748/wjg.v16.i21.2579 CrossRefGoogle Scholar
  23. 23.
    Dhingra R, Sullivan L, Jacques PF, Wang TJ, Fox CS, Meigs JB, D’Agostino RB, Gaziano JM, Vasan R (2007) Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation 116(5):480–488. doi: 10.1161/CIRCULATIONAHA.107.689935 CrossRefPubMedGoogle Scholar
  24. 24.
    Moeller SM, Fryhofer SA, Osbahr AJ (2009) The effects of high fructose syrup. J Am Coll Nutr 28:619–626CrossRefPubMedGoogle Scholar
  25. 25.
    Basaranoglu M, Basaranoglu G, Bugianesi E (2015) Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction. Hepat Surg Nutr 4(2):109–116. doi: 10.3978/j.issn.2304-3881.2014.11.05 Google Scholar
  26. 26.
    Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I (2009) Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 50:1094–1104. doi: 10.1002/hep.23122 CrossRefPubMedGoogle Scholar
  27. 27.
    Lê KA, Faeh D, Stettler R, Ith M, Kreis R, Vermathen P, Boesch C, Ravussin E, Tappy L (2006) A 4-wk high-fructose diet alters lipid metabolism without affecting insulin sensitivity or ectopic lipids in healthy humans. Am J Clin Nutr 84:1374–1379. doi: 10.3945/ajcn.2008.27336 PubMedGoogle Scholar
  28. 28.
    Lê KA, Ith M, Kreis R, Faeh D, Bortolotti M, Tran C, Boesch C, Tappy L (2009) Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes. Am J Clin Nutr 89:1760–1765. doi: 10.3945/ajcn.2008.27336 CrossRefPubMedGoogle Scholar
  29. 29.
    Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl AM, Johnson RJ, Abdelmalek MF (2008) Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 48:993–999. doi: 10.1016/j.jhep.2008.02.011 CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Petrie JL, Patman GL, Sinha I, Alexander TD, Reeves HL, Agius L (2013) The rate of production of uric acid by hepatocytes is a sensitive index of compromised cell ATP homeostasis. Am J Physiol Endocrinol Metab 305(10):E1255–E1265. doi: 10.1152/ajpendo.00214.2013 CrossRefPubMedGoogle Scholar
  31. 31.
    Moore JB, Gunn PJ, Fielding BA (2014) The role of dietary sugars and de novo lipogenesis in non-alcoholic fatty liver disease. Nutrients 6(12):5679–5703. doi: 10.3390/nu6125679 CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Adaramoye OA, Akanni OO (2016) Effects of long-term administration of aspartame on biochemical indices, lipid profile and redox status of cellular system of male rats. J Basic Clin Physiol Pharmacol 27(1):29–37. doi: 10.1515/jbcpp-2014-0130 CrossRefPubMedGoogle Scholar
  33. 33.
  34. 34.
    Zucconi S, Volpato C, Adinolfi F, Gandini E,Gentile E, Loi A, Fioriti L (2013) Gathering consumption data on specific consumer groups of energy drinks. 10(3). http://www.efsa.europa.eu/sites/default/files/scientific_output/files/main_documents/394e.pdf
  35. 35.
    Saab S, Mallam D, Cox GA, Tong MJ (2014) Impact of coffee on liver diseases: a systematic review. Liver Int 34(4):495–504. doi: 10.1111/liv.12304 CrossRefPubMedGoogle Scholar
  36. 36.
    Catalano D, Martines GF, Tonzuso A, Pirri C, Trovato FM, Trovato GM (2010) Protective role of coffee in non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci 55:3200–3206. doi: 10.1007/s10620-010-1143-3 CrossRefPubMedGoogle Scholar
  37. 37.
    Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA (2012) Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 55(2):429–436. doi: 10.1002/hep.24731 CrossRefPubMedGoogle Scholar
  38. 38.
    Dranoff JA, Feld JJ, Lavoie EG (2014) Fausther M. How does coffee prevent liver fibrosis? Biological plausibility for recent epidemiological observations. Hepatology 60(2):464–467. doi: 10.1002/hep.27032 CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Huang B, Kunkel D, El Kabany M (2014) Acute liver failure following one year of daily consumption of a sugar-free energy drink. ACG Case Rep J 1(4):214–216. doi: 10.14309/crj.2014.57 PubMedPubMedCentralGoogle Scholar
  40. 40.
    Hu M, Chu WCW, Yamashita S, Yeung DKW, Shi L, Wang D, Masuda D, Yang Y, Tomlinson B (2012) Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patients. J Lipid Res 53(4):802–809. doi: 10.1194/jlr.P023614 CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Ferreira SE, de Mello MT, Pompéia S, de Souza-Formigoni ML (2006) Effects of energy drink ingestion on alcohol intoxication. Alcohol Clin Exp Res 30(4):598–605. doi: 10.1111/j.1530-0277.2006.00070.x CrossRefPubMedGoogle Scholar
  42. 42.
    European Monitoring Centre for Drugs and Drug Addiction: Summary 2011 ESPAD Report (2012) Substance use Among Students in 36 European Countries. Publications Office of the European Union, Luxembourg. http://www.can.se/contentassets/8d8cb78bbd28493b9030c65c598e3301/the_2011_espad_report_full.pdf
  43. 43.
    European Monitoring Centre for Drugs and Drug Addiction: Summary 2011 ESPAD Report (2012) Substance use among students in 36 European countries. Publications Office of the European Union, LuxembourgGoogle Scholar
  44. 44.
    Nobili V, Pinzani M (2001) Alcoholic and non-alcoholic fatty liver in adolescents: a worrisome convergence. Alcohol Alcohol 46:627–629. doi: 10.1093/alcalc/agr074 CrossRefGoogle Scholar
  45. 45.
    Naimi TS, Brewer RD, Mokdad A (2013) Binge drinking among US adults. JAMA 289:70–75. doi: 10.1001/jama.289.1.70 Google Scholar
  46. 46.
    Morita Y, Ueno T, Sasaki N, Kuhara K, Yoshioka S, Tateishi Y, Nagata E, Kage M, Sata M (2005) Comparison of liver histology between patients with non-alcoholic steatohepatitis and patients with alcoholic steatohepatitis in Japan. Alcohol Clin Exp Res 277S–281S. doi:  10.1097/01.alc.0000191777.36629.33
  47. 47.
    Xu J, Lai K, Verlinsky A, Lugea A, French SW, Cooper MP, Ji C, Tsukamoto H (2011) Synergistic steatohepatitis by moderate obesity and alcohol in mice despite increased adiponectin and p-AMPK. J Hepatol 55:673–682. doi: 10.1016/j.jhep.2010.12.034 CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Galli A, Price D, Crabb D (1999) High-level expression of rat class I alcohol dehydrogenases is sufficient for ethanol-induced fat accumulation in transduced HeLa cells. Hepatology 29:1164–1170. doi: 10.1002/hep.510290420 CrossRefPubMedGoogle Scholar
  49. 49.
    Sachse B, Meinl W, Glatt H, Monien BH (2016) Ethanol and 4-methylpyrazole increase DNA adduct formation of furfuryl alcohol in FVB/N wild-type mice and in mice expressing human sulfotransferases 1A1/1A2. Carcinogenesis. 37(3):314–319. doi: 10.1093/carcin/bgw006 CrossRefPubMedGoogle Scholar
  50. 50.
    Grucza RA, Krueger RF, Racette SB, Norberg KE, Hipp PR, Bierut LJ (2010) The emerging link between alcoholism risk and obesity in the United States. Arch Gen Psychiatry 67(12):1301–1308. doi: 10.1002/hep.510290420 CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Frasinariu OE, Ceccarelli S, Alisi A (2013) Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies. Dig Liver Dis 45(7):543–551. doi: 10.1016/j.dld.2012.11.010 CrossRefPubMedGoogle Scholar
  52. 52.
    Koot BG, van der Baan-Slootweg OH, Vinke S, Bohte AE, Tamminga-Smeulders CL, Jansen PL, Stoker J, Benninga MA (2016) Intensive lifestyle treatment for non-alcoholic fatty liver disease in children with severe obesity: inpatient versus ambulatory treatment. Int J Obes (Lond) 40(1):51–57. doi: 10.1038/ijo.2015.175 CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Antonella Mosca
    • 2
  • Claudia Della Corte
    • 1
  • Maria Rita Sartorelli
    • 1
  • Francesca Ferretti
    • 1
  • Francesco Nicita
    • 3
  • Andrea Vania
    • 2
  • Valerio Nobili
    • 1
  1. 1.Hepato-Metabolic Disease UnitBambino Gesù Children’s Hospital, IRCCSRomeItaly
  2. 2.Department of Paediatrics and Paediatric Neuropsychiatry, Centre of Paediatric Dietetics and NutritionSapienza UniversityRomeItaly
  3. 3.Child Neurology Unit, Department of Paediatrics and Paediatric NeuropsychiatrySapienza UniversityRomeItaly

Personalised recommendations